Market Overview

Epiomic Epidemiology Report Acne Vulgaris Forecast In 19 Major Markets 2018-2028


Epiomic Epidemiology Report Acne Vulgaris Forecast In 19 Major Markets 2018-2028

PR Newswire

DUBLIN, July 25, 2018 /PRNewswire/ --

The "Epiomic Epidemiology Series: Acne Vulgaris Forecast In 19 Major Markets 2018-2028" report has been added to's offering.

Research and Markets Logo

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and, occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, main classes of the disease by severity, type and grade, as well as disease aetiology, manifestations and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

  • Underlying hormone imbalance
  • Puberty
  • Family history
  • Skin scarring

Reasons to buy

  • Able to quantify patient populations in global Acne Vulgaris market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris prevalent population.
  • Identify sub-populations within Acne Vulgaris which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Acne Vulgaris patients.

Key Topics Covered:

  1. Introduction
  2. Cause Of The Disease
  3. Risk Factors & Prevention
  4. Diagnosis Of The Disease
  5. Variation By Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key Comorbid Conditions / Features Associated With The Disease
  8. Methodology For Quantification Of Patient Numbers
  9. Top-Line Prevalence For Acne Vulgaris
  10. Features Of Acne Vulgaris Patients
  11. Abbreviations Used In The Report
  12. Other Services & Solutions
  13. Reports & Publications
  14. Online Epidemiology Databases
  15. Online Pharmaceutical Pricing Database
  16. References
  17. Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets

View Comments and Join the Discussion!